health
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows
Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases
TL;DR
- Relacorilant, a drug for Cushing's syndrome, showed a 35% reduction in the risk of death for patients with platinum-resistant ovarian cancer.
- Patients treated with relacorilant lived an average of four months longer than those receiving usual care.
- Pembrolizumab, an immunotherapy drug, also showed an average survival benefit of 3.7 months when used alongside usual care.
- Platinum-resistant ovarian cancer is an aggressive form where the disease progresses within six months of platinum-based chemotherapy.
- Both relacorilant and pembrolizumab have been approved in the US for treating platinum-resistant ovarian cancer, but require further testing for UK approval.